In Terni, an ambitious experiment is under way to defeat malaria: modifying the genes of the mosquito that carries the disease in order to compromise its reproductive capacity.
Malaria kills around half a million people every year and makes more than 200 million ill. Tragic numbers that have not fallen in recent years and that affect above all the countries of sub-Saharan Africa. The news spread by the World Health Organization regarding the testing of a likely vaccine being carried out in Malawi travelled around the world, but beyond this, further methods are being studied in an attempt to defeat the disease. Among these is the controversial attempt to release into the open air mosquitoes created in a laboratory — a form of research also being pursued in Italy, specifically in Terni.
At the Polo d'innovazione di genomica, genetica e biologia (Ggb) in Terni, research is under way aimed at creating mosquitoes with mutated genes. A group of 10 scientists has already carried out the first experiments, initially revealed in an article on the American website Npr. The project has attracted international interest, and not only because of the importance of the studies. The partner of Polo Ggb (a private company with public participation and no profit motive) is Target Malaria, the non-profit organisation funded by the Bill & Melinda Gates Foundation.
Il Polo GGB è protagonista di una cruciale fase di sperimentazione nell’ambito del progetto Target Malaria. Le camere climatiche del Laboratorio di Ecologia e Genetica ospitano zanzare Anopheles per testare la nuova tecnologia gene drive “double sex”. n.pr/2RUmWj9
The scientists at Polo Ggb continue their experiments, but concerned reactions to this practice have not been lacking. A study published in the journal British Medical Journal analyses the ethical problems that this type of innovation could bring, dwelling on the fact that "any ethical debate must involve the affected African parties living in malaria areas and consider future generations and the environment. The impact on biodiversity and ecosystems must be analysed when it comes to additions that interfere with biological entities. Genome editing technologies should happen only when their side effects and social impacts are sufficiently understood."
Other voices have been raised against this initiative, some of them coming directly from Africa. Journalist Zahra Moloo travelled to Burkina Faso to hear the opinions of local people: "mayors and citizens want to know what risks exist and what will happen once the mosquitoes have been released," Moloo reports in her article, "some local activists think that, rather than experimenting with genetic modification, the government should create good national sanitation." Target Malaria has always stated that it is in contact with local populations and has involved and consulted them in decisions. There is still a great deal to be done to defeat malaria, but one possible solution also runs through Italy.
Alekos Simoni, the Polo's scientific director, answered some questions about this unique research being conducted in Italy.
What is the situation with malaria in the world today? Despite the great progress made in recent years in reducing the incidence of and deaths caused by malaria — mainly thanks to the distribution of insecticide-treated bed nets — we are still far from the complete eradication of the disease, also because of a worrying and ever-growing phenomenon of resistance to the most common insecticides. The news of the release of the vaccine in Malawi, to be followed by Ghana and Kenya, is excellent news and we await the results of this intervention with confidence. Our plans do not change, because the vaccine currently available (RTS,S) unfortunately has limited efficacy [around 30 per cent, after 4 doses, ed.], and so it is considered by the World Health Organization a complementary intervention alongside all others in use and also alongside genetic control interventions, such as the one we are developing. The technology developed will then be made available to the countries that wish to use it.
What studies are you carrying out in Terni?
The technology is based on the genetic modification of the malaria-carrying mosquito in order to compromise its reproductive capacity and thus reduce its numbers. The underlying gene drive mechanism makes it possible to transfer this modification to entire mosquito populations effectively and efficiently through the release of a limited number of individuals. This technology is extremely precise because it allows only the species of mosquito of the genus Anopheles responsible for the transmission of malaria to be targeted, and not all the other thousands of mosquito species found in nature. Part of the scientific activities at Polo Ggb in Terni focuses on testing and evaluating the population dynamics of genetically modified Anopheles mosquitoes inside large cages held in climate-controlled chambers that perfectly replicate subtropical environmental conditions in terms of light, humidity and temperature. These experiments make it possible to build mathematical models to predict the ability of released mosquitoes to reduce population density in nature.
Is it possible that once in nature the modified mosquitoes could pass the gene to other animal species?
The gene-drive technology is based on the mating and reproduction of mosquitoes, so only mosquitoes that can interbreed with one another can receive the modification. In nature there are more than 3,000 species of mosquito but only a very small proportion — around twenty — can transmit malaria. Only certain mosquitoes of the genus Anopheles, and in particular only those of the gambiae group, can mate in nature with the modified mosquitoes that will be released, and so only these are the target of our technology, and all of them are malaria carriers. Based on current knowledge, Anopheles gambiae mosquitoes do not appear to play any key role in the ecosystem. Target Malaria has nonetheless begun an important programme of research to study in detail the role of these mosquitoes in the ecosystem and to understand the potential impact of their reduction in nature.
By when do you plan to test the modified mosquitoes in nature, and will the first time be in Africa?
At the moment the technology that Target Malaria is developing is still in the research and development phase. It will take around 8–10 years before it can be used in the field. We are developing the genetic technology targeting three species of mosquito of the genus Anopheles (A. gambiae, A. coluzzii, and A. arabiensis) that are responsible for the majority of malaria transmission in Africa, where 90 per cent of cases occur. The three mosquito species are found exclusively in Africa.
If released into the wild and everything went as planned, how long would it take before a significant reduction in the spread of malaria was seen?
Target Malaria is developing this genetic technology in three stages, which will be tested in the field consecutively. The first two stages are transitional phases in which the released mosquitoes will persist in the wild for a short or very short time and will have no impact on the spread of malaria. These stages are fundamental to the development of the technology and to obtaining the field data needed for the release of the third phase of gene drive mosquitoes, which will have a significant impact on reducing malaria. According to current mathematical models, within 3-4 years of release there could already be a substantial reduction in malaria-carrying mosquitoes and therefore in the transmission of the disease. This third stage will not be released before 2028, and only if all permits are obtained from the relevant national and international bodies and all efficacy and safety tests for humans and nature have been passed.
Italy is working to reduce the number of malaria-carrying mosquitoes
Well-being — di Andrea Indiano
In Terni, an ambitious experiment is under way to defeat malaria: modifying the genes of the mosquito that carries the disease in order to compromise its reproductive capacity.